This article needs additional citations for verification. (July 2009) |
Clinical data | |
---|---|
ATC code | |
Pharmacokinetic data | |
Excretion | Renal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.003.690 |
Chemical and physical data | |
Formula | C14H16N4O3+2 |
Molar mass | 288.307 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Obidoxime is a member of the oxime family used to treat organophosphate poisoning. Oximes are drugs known for their ability to reverse the binding of organophosphorus compounds to the enzyme acetylcholinesterase (AChE).[1]
AChE is an enzyme that removes acetylcholine from the synapse after it creates the required stimulation on the next nerve cell. If it gets inhibited, acetylcholine is not removed after the stimulation and multiple stimulations are made, resulting in muscle contractions and paralysis.
Organophosphates such as nerve gases are well-known inhibitors of AChE. They bind to a specific place on the enzyme and prevent it from functioning normally by changing the OH group on the serine residue and by protonating (quaternary nitrogen, R4N+) the nearby nitrogen atom located in the histidine residue.
{{cite journal}}
: CS1 maint: unfit URL (link)